New mRNA vaccine aims to stop cancer recurrence in High-Risk patients
⭐️ VACCINE ⭐️
Recruiting now
This early-phase study tests a personalized mRNA vaccine (RGL-270) designed to train the immune system to recognize and attack leftover cancer cells after standard treatment. It is for adults aged 18-75 with solid tumors who have a high risk of recurrence. The vaccine is given al…
Phase: PHASE1 • Sponsor: Xian-Jun Yu • Aim: ⭐️ VACCINE ⭐️
Last updated May 12, 2026 13:42 UTC